Please enable JavaScript to continue using this application.

Compare $ABUS vs $XENE | Chartloom

Compare

$ABUS vs $XENE

Arbutus Biopharma Corp · Xenon Pharmaceuticals Inc

ABUS

Arbutus Biopharma Corp

XENE

Xenon Pharmaceuticals Inc

Compare $ABUS vs $XENE

Comparing Arbutus Biopharma Corp and Xenon Pharmaceuticals Inc

ABUSArbutus Biopharma Corp

XENEXenon Pharmaceuticals Inc

ABUSArbutus Biopharma Corp

Market cap

$834M

P/E (TTM)

5.44x

Forward P/E (NTM)

—

Forward P/S (NTM)

204.32x

Rev growth (TTM)

1078.8%

YTD performance

-11.5%

52W performance

1.0%

FCF yield

-3.0%

XENEXenon Pharmaceuticals Inc

Market cap

$3.52B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1,117.23x

Rev growth (TTM)

-100.0%

YTD performance

-18.1%

52W performance

-7.2%

FCF yield

-9.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ABUS

XENE

Detailed metrics comparison

ABUS

Arbutus Biopharma Corp

XENE

Xenon Pharmaceuticals Inc

Market Cap

ABUS$834M

XENE$3.52B

Enterprise Value

ABUS$818M

XENE$3.40B

Price

ABUS$4.22

XENE$36.44

P/E Ratio

ABUS5.44x

XENEN/A

P/S Ratio

ABUS4.59x

XENE497.55x

EV/Sales

ABUS4.50x

XENE481.61x

EV/EBITDA

ABUS4.98x

XENE0.00x

P/B Ratio

ABUS3.41x

XENE3.00x

P/FCF Ratio

ABUSN/A

XENEN/A

EV/FCF

ABUS-33.20x

XENE-10.05x

PEG Ratio

ABUSN/A

XENEN/A

Forward P/E (NTM)

ABUSN/A

XENEN/A

Forward P/S (NTM)

ABUS204.32x

XENE1,117.23x

Revenue (TTM)

ABUS$182M

XENE$0

Revenue Growth (YoY)

ABUS1078.8%

XENE-100.0%

Forward Rev Growth

ABUS-97.7%

XENE2407.0%

Gross Margin (TTM)

ABUS0.0%

XENE0.0%

Operating Margin (TTM)

ABUS82.0%

XENE0.0%

EBITDA Margin (TTM)

ABUS82.2%

XENE0.0%

Net Margin (TTM)

ABUS84.2%

XENE0.0%

FCF Margin (TTM)

ABUS-13.6%

XENEN/A

Net Income (TTM)

ABUS$153M

XENE$-409M

FCF (TTM)

ABUS$-25M

XENE$-339M

EPS (TTM)

ABUS$0.78

XENE-$4.11

ROE (TTM)

ABUS91.0%

XENE-4398.0%

ROA (TTM)

ABUS82.3%

XENE-4172.0%

ROIC (TTM)

ABUS89.2%

XENE-4398.0%

Cash

ABUS$19M

XENE$120M

Debt

ABUS$3M

XENE$0

Net Cash/Debt

ABUS$16M

XENE$120M

Current Ratio (TTM)

ABUS81.42x

XENE21.02x

Quick Ratio (TTM)

ABUS80.97x

XENE20.71x

Debt/Equity (TTM)

ABUS0.01x

XENE0.00x

Debt/Assets (TTM)

ABUS0.0%

XENE0.0%

Interest Coverage (TTM)

ABUSN/A

XENEN/A

Net Debt/EBITDA (TTM)

ABUS0.00x

XENE0.00x

Beta

ABUS0.79

XENE0.08

52W Performance

ABUS1.0%

XENE-7.2%

YTD Performance

ABUS-11.5%

XENE-18.1%

% from 52W High

ABUS-22.6%

XENE-49.8%

% from 52W Low

ABUS20.6%

XENE3.9%

Asset Turnover (TTM)

ABUS0.98x

XENE0.01x

FCF Yield (TTM)

ABUS-3.0%

XENE-9.6%

Earnings Yield (TTM)

ABUS18.4%

XENE-11.6%

Dividend Yield (TTM)

ABUSN/A

XENEN/A

Rule of 40

ABUS1,065.2

XENE-100.0

EV/GP/RG

ABUSN/A

XENEN/A

Ticker research

View ABUS research View XENE research

Metric	ABUS Arbutus Biopharma Corp	XENE Xenon Pharmaceuticals Inc
Market & Valuation
Market Cap	$834M	$3.52B
Enterprise Value	$818M	$3.40B
Price	$4.22	$36.44
P/E Ratio	5.44x	N/A
P/S Ratio	4.59x	497.55x
EV/Sales	4.50x	481.61x
EV/EBITDA	4.98x	0.00x
P/B Ratio	3.41x	3.00x
P/FCF Ratio	N/A	N/A
EV/FCF	-33.20x	-10.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	204.32x	1,117.23x
Revenue & Growth
Revenue (TTM)	$182M	$0
Revenue Growth (YoY)	1078.8%	-100.0%
Forward Rev Growth	-97.7%	2407.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	82.0%	0.0%
EBITDA Margin (TTM)	82.2%	0.0%
Net Margin (TTM)	84.2%	0.0%
FCF Margin (TTM)	-13.6%	N/A
Net Income (TTM)	$153M	$-409M
FCF (TTM)	$-25M	$-339M
EPS (TTM)	$0.78	-$4.11
ROE (TTM)	91.0%	-4398.0%
ROA (TTM)	82.3%	-4172.0%
ROIC (TTM)	89.2%	-4398.0%
Financial Health
Cash	$19M	$120M
Debt	$3M	$0
Net Cash/Debt	$16M	$120M
Current Ratio (TTM)	81.42x	21.02x
Quick Ratio (TTM)	80.97x	20.71x
Debt/Equity (TTM)	0.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.79	0.08
52W Performance	1.0%	-7.2%
YTD Performance	-11.5%	-18.1%
% from 52W High	-22.6%	-49.8%
% from 52W Low	20.6%	3.9%
Efficiency & Yields
Asset Turnover (TTM)	0.98x	0.01x
FCF Yield (TTM)	-3.0%	-9.6%
Earnings Yield (TTM)	18.4%	-11.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	1,065.2	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View ABUS research	View XENE research

Valuation

P/E Ratio

ABUS

5.44x

P/S Ratio

ABUS

4.59x

XENE

497.55x

EV/FCF

ABUS

-33.20x

XENE

-10.05x

Growth & revenue

Revenue Growth TTM

ABUS

1078.8%

XENE

-100.0%

Forward Revenue Growth

XENE

2407.0%

ABUS

-97.7%

Profitability & performance

Gross Margin

ABUS

0.0%

XENE

0.0%

ROE

ABUS

91.0%

XENE

-4398.0%

FCF Yield %

ABUS

-3.0%

XENE

-9.6%

52-Week Performance

ABUS

1.0%

XENE

-7.2%

Detailed metrics comparison

ABUS

Arbutus Biopharma Corp

XENE

Xenon Pharmaceuticals Inc

Market Cap

ABUS$834M

XENE$3.52B

Enterprise Value

ABUS$818M

XENE$3.40B

Price

ABUS$4.22

XENE$36.44

P/E Ratio

ABUS5.44x

XENEN/A

P/S Ratio

ABUS4.59x

XENE497.55x

EV/Sales

ABUS4.50x

XENE481.61x

EV/EBITDA

ABUS4.98x

XENE0.00x

P/B Ratio

ABUS3.41x

XENE3.00x

P/FCF Ratio

ABUSN/A

XENEN/A

EV/FCF

ABUS-33.20x

XENE-10.05x

PEG Ratio

ABUSN/A

XENEN/A

Forward P/E (NTM)

ABUSN/A

XENEN/A

Forward P/S (NTM)

ABUS204.32x

XENE1,117.23x

Revenue (TTM)

ABUS$182M

XENE$0

Revenue Growth (YoY)

ABUS1078.8%

XENE-100.0%

Forward Rev Growth

ABUS-97.7%

XENE2407.0%

Gross Margin (TTM)

ABUS0.0%

XENE0.0%

Operating Margin (TTM)

ABUS82.0%

XENE0.0%

EBITDA Margin (TTM)

ABUS82.2%

XENE0.0%

Net Margin (TTM)

ABUS84.2%

XENE0.0%

FCF Margin (TTM)

ABUS-13.6%

XENEN/A

Net Income (TTM)

ABUS$153M

XENE$-409M

FCF (TTM)

ABUS$-25M

XENE$-339M

EPS (TTM)

ABUS$0.78

XENE-$4.11

ROE (TTM)

ABUS91.0%

XENE-4398.0%

ROA (TTM)

ABUS82.3%

XENE-4172.0%

ROIC (TTM)

ABUS89.2%

XENE-4398.0%

Cash

ABUS$19M

XENE$120M

Debt

ABUS$3M

XENE$0

Net Cash/Debt

ABUS$16M

XENE$120M

Current Ratio (TTM)

ABUS81.42x

XENE21.02x

Quick Ratio (TTM)

ABUS80.97x

XENE20.71x

Debt/Equity (TTM)

ABUS0.01x

XENE0.00x

Debt/Assets (TTM)

ABUS0.0%

XENE0.0%

Interest Coverage (TTM)

ABUSN/A

XENEN/A

Net Debt/EBITDA (TTM)

ABUS0.00x

XENE0.00x

Beta

ABUS0.79

XENE0.08

52W Performance

ABUS1.0%

XENE-7.2%

YTD Performance

ABUS-11.5%

XENE-18.1%

% from 52W High

ABUS-22.6%

XENE-49.8%

% from 52W Low

ABUS20.6%

XENE3.9%

Asset Turnover (TTM)

ABUS0.98x

XENE0.01x

FCF Yield (TTM)

ABUS-3.0%

XENE-9.6%

Earnings Yield (TTM)

ABUS18.4%

XENE-11.6%

Dividend Yield (TTM)

ABUSN/A

XENEN/A

Rule of 40

ABUS1,065.2

XENE-100.0

EV/GP/RG

ABUSN/A

XENEN/A

Ticker research

View ABUS research View XENE research

Metric	ABUS Arbutus Biopharma Corp	XENE Xenon Pharmaceuticals Inc
Market & Valuation
Market Cap	$834M	$3.52B
Enterprise Value	$818M	$3.40B
Price	$4.22	$36.44
P/E Ratio	5.44x	N/A
P/S Ratio	4.59x	497.55x
EV/Sales	4.50x	481.61x
EV/EBITDA	4.98x	0.00x
P/B Ratio	3.41x	3.00x
P/FCF Ratio	N/A	N/A
EV/FCF	-33.20x	-10.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	204.32x	1,117.23x
Revenue & Growth
Revenue (TTM)	$182M	$0
Revenue Growth (YoY)	1078.8%	-100.0%
Forward Rev Growth	-97.7%	2407.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	82.0%	0.0%
EBITDA Margin (TTM)	82.2%	0.0%
Net Margin (TTM)	84.2%	0.0%
FCF Margin (TTM)	-13.6%	N/A
Net Income (TTM)	$153M	$-409M
FCF (TTM)	$-25M	$-339M
EPS (TTM)	$0.78	-$4.11
ROE (TTM)	91.0%	-4398.0%
ROA (TTM)	82.3%	-4172.0%
ROIC (TTM)	89.2%	-4398.0%
Financial Health
Cash	$19M	$120M
Debt	$3M	$0
Net Cash/Debt	$16M	$120M
Current Ratio (TTM)	81.42x	21.02x
Quick Ratio (TTM)	80.97x	20.71x
Debt/Equity (TTM)	0.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.79	0.08
52W Performance	1.0%	-7.2%
YTD Performance	-11.5%	-18.1%
% from 52W High	-22.6%	-49.8%
% from 52W Low	20.6%	3.9%
Efficiency & Yields
Asset Turnover (TTM)	0.98x	0.01x
FCF Yield (TTM)	-3.0%	-9.6%
Earnings Yield (TTM)	18.4%	-11.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	1,065.2	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View ABUS research	View XENE research